Key Highlights

  • Verrica Pharmaceuticals shares settled up 12% at $5.66.
  • The company finished enrollment in COVE-2, its first Phase 3 pivotal study of YCANTH in common warts.
  • Topline data is guided to Q1 2027.
  • A second Phase 3 study, COVE-3, is past halfway and slated for mid-2027 data.

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares settled up 12% at $5.66 after the company finished enrollment in COVE-2, the first Phase 3 pivotal study of YCANTH (cantharidin) in common warts.

What Happened

Topline data from COVE-2 is guided to Q1 2027. COVE-3, the second Phase 3 study, is past the halfway point and slated for mid-2027 data, which would support a supplemental filing if both studies succeed. YCANTH is already commercially available for molluscum, meaning this represents a label expansion opportunity rather than a new molecule.

Market Reaction

Shares rose as completing enrollment removed time-risk from the program, with common warts representing a large, underserved dermatology market for an already-approved formulation.

Outlook

Topline data from COVE-2, expected in Q1 2027, represents the next major catalyst, with COVE-3 data following in mid-2027 to potentially support a supplemental filing.